Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Modus Therapeutics secures $15.7m for sickle cell disease drug development Modus Therapeutics, a Swedish biotech firm specializing in sickle cell disease therapies, has successfully raised SEK 140 million… bypharmanewsdailyJuly 15, 2018